Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Natalia Olchanski

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
American Journal of Preventive Medicine|December 1, 2012
A role for research: an observation on preventive services for womenNatalia Olchanski, Joshua T Cohen, Peter J Neumann
Infection Control and Hospital Epidemiology|April 5, 2011
Assessment of the influence of test characteristics on the clinical and cost impacts of methicillin-resistant Staphylococcus aureus screening programs in US hospitalsNatalia Olchanski, Charles Mathews, Lauren Fusfeld, et al.
International Journal of Cardiology|November 22, 2019
Two-year outcomes and cost for heart failure patients following discharge from the hospital after an acute heart failure admissionNatalia Olchanski, Amanda R Vest, Joshua T Cohen, et al.
Cardiovascular Endocrinology & Metabolism|February 28, 2020
Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetesNatalia Olchanski, Amanda R Vest, Joshua T Cohen, et al.
Medrxiv : the Preprint Server for Health Sciences|December 8, 2025
Estimating the Risk-Based Value of the Diabetes Prevention Program: How well does clinical trial-based cost-effectiveness apply to the real world?Natalia Olchanski, Samuel B Weidner, Ching-Hsuan Lin, et al.
The American Journal of Managed Care|October 9, 2014
Potential role of network meta-analysis in value-based insurance designJames D Chambers, Aaron Winn, Yue Zhong, et al.
Hospital Practice (1995)|November 12, 2010
Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospitalNatalia Olchanski, Katherine A Slawsky, Stephanie Plent, et al.
International Journal of Cardiology|April 17, 2018
Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissionsNatalia Olchanski, Amanda R Vest, Joshua T Cohen, et al.
Journal of Managed Care & Specialty Pharmacy|June 23, 2022
When are breakthrough therapies cost-effective?Natalia Olchanski, Pei-Jung Lin, Wei-Shi Yeh, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 20, 2015
The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncologyNatalia Olchanski, Yue Zhong, Joshua T Cohen, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
American Journal of Preventive Medicine|December 1, 2012
A role for research: an observation on preventive services for womenNatalia Olchanski, Joshua T Cohen, Peter J Neumann
Infection Control and Hospital Epidemiology|April 5, 2011
Assessment of the influence of test characteristics on the clinical and cost impacts of methicillin-resistant Staphylococcus aureus screening programs in US hospitalsNatalia Olchanski, Charles Mathews, Lauren Fusfeld, et al.
International Journal of Cardiology|November 22, 2019
Two-year outcomes and cost for heart failure patients following discharge from the hospital after an acute heart failure admissionNatalia Olchanski, Amanda R Vest, Joshua T Cohen, et al.
Cardiovascular Endocrinology & Metabolism|February 28, 2020
Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetesNatalia Olchanski, Amanda R Vest, Joshua T Cohen, et al.
Medrxiv : the Preprint Server for Health Sciences|December 8, 2025
Estimating the Risk-Based Value of the Diabetes Prevention Program: How well does clinical trial-based cost-effectiveness apply to the real world?Natalia Olchanski, Samuel B Weidner, Ching-Hsuan Lin, et al.
The American Journal of Managed Care|October 9, 2014
Potential role of network meta-analysis in value-based insurance designJames D Chambers, Aaron Winn, Yue Zhong, et al.
Hospital Practice (1995)|November 12, 2010
Economic impact of switching to bivalirudin for a primary percutaneous coronary intervention in a US hospitalNatalia Olchanski, Katherine A Slawsky, Stephanie Plent, et al.
International Journal of Cardiology|April 17, 2018
Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissionsNatalia Olchanski, Amanda R Vest, Joshua T Cohen, et al.
Journal of Managed Care & Specialty Pharmacy|June 23, 2022
When are breakthrough therapies cost-effective?Natalia Olchanski, Pei-Jung Lin, Wei-Shi Yeh, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|October 20, 2015
The peculiar economics of life-extending therapies: a review of costing methods in health economic evaluations in oncologyNatalia Olchanski, Yue Zhong, Joshua T Cohen, et al.
Pageof 3